LENSAR (NASDAQ:LNSR – Get Free Report) had its target price lifted by equities researchers at BTIG Research from $9.00 to $10.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential upside of 14.68% from the company’s current price.
A number of other brokerages have also weighed in on LNSR. Wall Street Zen raised LENSAR from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reissued a “sell (d+)” rating on shares of LENSAR in a research report on Friday, August 7th. Finally, Lake Street Capital restated a “buy” rating and set a $13.00 price target on shares of LENSAR in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, LENSAR currently has an average rating of “Hold” and a consensus target price of $11.50.
View Our Latest Stock Analysis on LNSR
LENSAR Price Performance
LENSAR (NASDAQ:LNSR – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.26. The firm had revenue of $16.50 million during the quarter, compared to analyst estimates of $14.65 million. LENSAR had a negative return on equity of 529.08% and a net margin of 57.57%.
Hedge Funds Weigh In On LENSAR
Several institutional investors have recently bought and sold shares of LNSR. Brandes Investment Partners LP raised its stake in LENSAR by 10.1% in the fourth quarter. Brandes Investment Partners LP now owns 856,216 shares of the company’s stock worth $9,958,000 after buying an additional 78,513 shares in the last quarter. Vanguard Group Inc. boosted its position in LENSAR by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 507,603 shares of the company’s stock valued at $6,269,000 after acquiring an additional 1,446 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of LENSAR by 103.9% in the 2nd quarter. Geode Capital Management LLC now owns 219,373 shares of the company’s stock valued at $2,890,000 after acquiring an additional 111,802 shares during the period. Groupe la Francaise increased its holdings in shares of LENSAR by 16.2% in the 1st quarter. Groupe la Francaise now owns 213,537 shares of the company’s stock valued at $1,273,000 after acquiring an additional 29,813 shares during the period. Finally, BlackRock Inc. bought a new position in shares of LENSAR in the 2nd quarter worth $1,057,000. 40.15% of the stock is owned by hedge funds and other institutional investors.
LENSAR Company Profile
LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.
Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.
Featured Stories
- Five stocks we like better than LENSAR
- One Platform, Every Ailment: Hinge Health’s Gamble
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
